Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Kidney Cancer | Research article

Tumor volume: a new prognostic factor of oncological outcome of localized clear cell renal cell carcinoma

Authors: Shao-Hao Chen, Long-Yao Xu, Yu-Peng Wu, Zhi-Bin Ke, Peng Huang, Fei Lin, Xiao-Dong Li, Xue-Yi Xue, Yong Wei, Qing-Shui Zheng, Ning Xu

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Clear cell renal cell carcinoma (ccRCC) is one of the most frequent malignancies; however, the present prognostic factors was deficient. This study aims to explore whether there is a relationship between tumor volume (TV) and oncological outcomes for localized ccRCC.

Methods

Seven hundred forty-nine localized ccRCC patients underwent surgery in our hospital. TV was outlined and calculated using a three-dimensional conformal radiotherapy planning system. We used receiver operating characteristic (ROC) curves to identified optimal cut-off value. Univariable and multivariable Cox regression models were performed to explore the association between TV and oncological outcomes. Kaplan-Meier method and log-rank test were used to estimate survival probabilities and determine the significance, respectively. Time-dependent ROC curve was utilized to assess the prognostic effect.

Results

Log rank test showed that higher Fuhrman grade, advanced pT classification and higher TV were associated with shortened OS, cancer-specific survival (CSS), freedom from metastasis (FFM) and freedom from local recurrence (FFLR). multivariable analysis showed higher Fuhrman grade and higher TV were predictors of adverse OS and CSS. The AUC of TV for FFLR was 0.822. The AUC of TV (0.864) for FFM was higher than that of pT classification (0.818) and Fuhrman grade (0.803). For OS and CSS, the AUC of TV was higher than that of Fuhrman grade (0.832 vs. 0.799; 0.829 vs 0.790).

Conclusions

High TV was an independent predictor of poor CSS, OS, FFLR and FFM of localized ccRCC. Compared with pT classification and Fuhrman grade, TV could be a new and better prognostic factor of oncological outcome of localized ccRCC, which might contribute to tailored follow-up or management strategies.
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.CrossRef
2.
go back to reference Chen YH, Chen SH, Hou J, Ke ZB, Wu YP, Lin TT, Wei Y, Xue XY, Zheng QS, Huang JB, et al. Identifying hub genes of clear cell renal cell carcinoma associated with the proportion of regulatory T cells by weighted gene co-expression network analysis. Aging. 2019;11(21):9478–91.CrossRef Chen YH, Chen SH, Hou J, Ke ZB, Wu YP, Lin TT, Wei Y, Xue XY, Zheng QS, Huang JB, et al. Identifying hub genes of clear cell renal cell carcinoma associated with the proportion of regulatory T cells by weighted gene co-expression network analysis. Aging. 2019;11(21):9478–91.CrossRef
3.
go back to reference Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24.CrossRef Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24.CrossRef
4.
go back to reference Chen SH, Wu YP, Li XD, Lin T, Guo QY, Chen YH, Huang JB, Wei Y, Xue XY, Zheng QS, et al. R.E.N.a.L. Nephrometry score: a preoperative risk factor predicting the Fuhrman grade of clear-cell renal carcinoma. J Cancer. 2017;8(18):3725–32.CrossRef Chen SH, Wu YP, Li XD, Lin T, Guo QY, Chen YH, Huang JB, Wei Y, Xue XY, Zheng QS, et al. R.E.N.a.L. Nephrometry score: a preoperative risk factor predicting the Fuhrman grade of clear-cell renal carcinoma. J Cancer. 2017;8(18):3725–32.CrossRef
5.
go back to reference Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2011;59(1):18–23.CrossRef Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2011;59(1):18–23.CrossRef
6.
go back to reference Kim SP, Alt AL, Weight CJ, Costello BA, Cheville JC, Lohse C, Allmer C, Leibovich BC. Independent validation of the 2010 American joint committee on Cancer TNM classification for renal cell carcinoma: results from a large, Single Institution Cohort. J Urol. 2011;185(6):2035–9.CrossRef Kim SP, Alt AL, Weight CJ, Costello BA, Cheville JC, Lohse C, Allmer C, Leibovich BC. Independent validation of the 2010 American joint committee on Cancer TNM classification for renal cell carcinoma: results from a large, Single Institution Cohort. J Urol. 2011;185(6):2035–9.CrossRef
7.
go back to reference Ke ZB, Chen SH, Chen YH, Wu YP, Lin F, Xue XY, Zheng QS, Xu N, Wei Y. Risk factors for brain metastases in patients with renal cell carcinoma. Biomed Res Int. 2020;2020:6836234.PubMedPubMedCentral Ke ZB, Chen SH, Chen YH, Wu YP, Lin F, Xue XY, Zheng QS, Xu N, Wei Y. Risk factors for brain metastases in patients with renal cell carcinoma. Biomed Res Int. 2020;2020:6836234.PubMedPubMedCentral
8.
go back to reference Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018;36(12):1943–52.CrossRef Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018;36(12):1943–52.CrossRef
9.
go back to reference Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, et al. Kidney Cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(6):804–34.CrossRef Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, et al. Kidney Cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(6):804–34.CrossRef
10.
go back to reference Benson AB III, D’Angelica MI, Abbott DE, et al. Hepatobiliary Cancers, Version 1.2017: Featured Updates to the NCCN Guidelines[J]. J Natl Comprehen Cancer Network. 2017;15(5):563.CrossRef Benson AB III, D’Angelica MI, Abbott DE, et al. Hepatobiliary Cancers, Version 1.2017: Featured Updates to the NCCN Guidelines[J]. J Natl Comprehen Cancer Network. 2017;15(5):563.CrossRef
11.
go back to reference Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol. 2010;28(3):319–27.CrossRef Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol. 2010;28(3):319–27.CrossRef
12.
go back to reference Halachmi S, Moskovitz B, Farfara R, Nativ O. Predictors and mechanisms of oncological failure following nephron-sparing surgery for renal cancer. Isr Med Assoc J. 2011;13(3):166–71.PubMed Halachmi S, Moskovitz B, Farfara R, Nativ O. Predictors and mechanisms of oncological failure following nephron-sparing surgery for renal cancer. Isr Med Assoc J. 2011;13(3):166–71.PubMed
13.
go back to reference Haferkamp A, Kurosch M, Pritsch M, Hatiboglu G, Macher-Goeppinger S, Pfitzenmaier J, Pahernik S, Wagener N, Hohenfellner M. Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications. Ann Surg Oncol. 2010;17(2):544–51.CrossRef Haferkamp A, Kurosch M, Pritsch M, Hatiboglu G, Macher-Goeppinger S, Pfitzenmaier J, Pahernik S, Wagener N, Hohenfellner M. Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications. Ann Surg Oncol. 2010;17(2):544–51.CrossRef
14.
go back to reference Yang B, Xia H, Xu C, Lu M, Zhang S, Wang G, Ma L. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically. BMC Urol. 2020;20(1):14.CrossRef Yang B, Xia H, Xu C, Lu M, Zhang S, Wang G, Ma L. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically. BMC Urol. 2020;20(1):14.CrossRef
15.
go back to reference Bedke J, Heide J, Ribback S, Rausch S, de Martino M, Scharpf M, Haitel A, Zimmermann U, Pechoel M, Alkhayyat H, et al. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. BJU Int. 2018;121(1):84–92.CrossRef Bedke J, Heide J, Ribback S, Rausch S, de Martino M, Scharpf M, Haitel A, Zimmermann U, Pechoel M, Alkhayyat H, et al. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. BJU Int. 2018;121(1):84–92.CrossRef
16.
go back to reference Haidar GM, Hicks TD, El-Sayed HF, Davies MG. Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. J Vasc SurgVenous Lymphat Dis. 2017;5(3):430–6.CrossRef Haidar GM, Hicks TD, El-Sayed HF, Davies MG. Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. J Vasc SurgVenous Lymphat Dis. 2017;5(3):430–6.CrossRef
17.
go back to reference Simmons MN, Fergany AF, Campbell SC. Effect of parenchymal volume preservation on kidney function after partial nephrectomy. J Urol. 2011;186(2):405–10.CrossRef Simmons MN, Fergany AF, Campbell SC. Effect of parenchymal volume preservation on kidney function after partial nephrectomy. J Urol. 2011;186(2):405–10.CrossRef
18.
go back to reference Sharma N, O’Hara J, Novick AC, Lieber M, Remer EM, Herts BR. Correlation between loss of renal function and loss of renal volume after partial nephrectomy for tumor in a solitary kidney. J Urol. 2008;179(4):1284–8.CrossRef Sharma N, O’Hara J, Novick AC, Lieber M, Remer EM, Herts BR. Correlation between loss of renal function and loss of renal volume after partial nephrectomy for tumor in a solitary kidney. J Urol. 2008;179(4):1284–8.CrossRef
19.
go back to reference Tobert CM, Boelkins B, Culver S, Mammen L, Kahnoski RJ, Lane BR. Surgeon assessment of renal preservation with partial nephrectomy provides information comparable to measurement of volume preservation with 3-dimensional image analysis. J Urol. 2014;191(5):1218–24.CrossRef Tobert CM, Boelkins B, Culver S, Mammen L, Kahnoski RJ, Lane BR. Surgeon assessment of renal preservation with partial nephrectomy provides information comparable to measurement of volume preservation with 3-dimensional image analysis. J Urol. 2014;191(5):1218–24.CrossRef
20.
go back to reference Shin TY, Komninos C, Kim DW, So KS, Bang KS, Jeong HJ, Han WK, Hong SJ, Jung BH, Lim SK, et al. A novel mathematical model to predict the severity of postoperative functional reduction before partial nephrectomy: the importance of calculating resected and ischemic volume. J Urol. 2015;193(2):423–9.CrossRef Shin TY, Komninos C, Kim DW, So KS, Bang KS, Jeong HJ, Han WK, Hong SJ, Jung BH, Lim SK, et al. A novel mathematical model to predict the severity of postoperative functional reduction before partial nephrectomy: the importance of calculating resected and ischemic volume. J Urol. 2015;193(2):423–9.CrossRef
21.
go back to reference Secil M, Cullu N, Aslan G, Mungan U, Uysal F, Tuna B, Yorukoglu K. The effect of tumor volume on survival in patients with renal cell carcinoma. Diagn Interv Radiol (Ankara, Turkey). 2012;18(5):480–7. Secil M, Cullu N, Aslan G, Mungan U, Uysal F, Tuna B, Yorukoglu K. The effect of tumor volume on survival in patients with renal cell carcinoma. Diagn Interv Radiol (Ankara, Turkey). 2012;18(5):480–7.
22.
go back to reference Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862.CrossRef Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862.CrossRef
23.
go back to reference Jiang T, Wu Y-P, Chen S-H, Ke Z-B, Liang Y-C, Xu N. Prognosis and clinicopathological characteristics of renal cell carcinoma: does bilateral occurrence influence overall and cancer-specific survival? Transl Cancer Res. 2019;9(2):432–40.CrossRef Jiang T, Wu Y-P, Chen S-H, Ke Z-B, Liang Y-C, Xu N. Prognosis and clinicopathological characteristics of renal cell carcinoma: does bilateral occurrence influence overall and cancer-specific survival? Transl Cancer Res. 2019;9(2):432–40.CrossRef
24.
go back to reference Shah PH, Moreira DM, Okhunov Z, Patel VR, Chopra S, Razmaria AA, Alom M, George AK, Yaskiv O, Schwartz MJ, et al. Positive surgical margins increase risk of recurrence after partial nephrectomy for high risk renal tumors. J Urol. 2016;196(2):327–34.CrossRef Shah PH, Moreira DM, Okhunov Z, Patel VR, Chopra S, Razmaria AA, Alom M, George AK, Yaskiv O, Schwartz MJ, et al. Positive surgical margins increase risk of recurrence after partial nephrectomy for high risk renal tumors. J Urol. 2016;196(2):327–34.CrossRef
25.
go back to reference Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–63.CrossRef Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–63.CrossRef
26.
go back to reference Jorns J, Thiel DD, Lohse CM, Williams A, Arnold ML, Cheville JC, Leibovich BC, Parker AS. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma. BJU Int. 2012;110(7):956–60.CrossRef Jorns J, Thiel DD, Lohse CM, Williams A, Arnold ML, Cheville JC, Leibovich BC, Parker AS. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma. BJU Int. 2012;110(7):956–60.CrossRef
27.
go back to reference Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, Joyce N, Schell MC, Milano MT. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis. 2014;6(4):369–74.PubMedPubMedCentral Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, Joyce N, Schell MC, Milano MT. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis. 2014;6(4):369–74.PubMedPubMedCentral
28.
go back to reference Rey Rey J, Leon Ramirez D, Lopez Garcia S, Fernandez Vazquez P, Benavente Delgado J, Ojea Calvo A. Pathological prognostic indicators in renal cell carcinoma. Actas Urol Esp. 2010;34(1):71–7.CrossRef Rey Rey J, Leon Ramirez D, Lopez Garcia S, Fernandez Vazquez P, Benavente Delgado J, Ojea Calvo A. Pathological prognostic indicators in renal cell carcinoma. Actas Urol Esp. 2010;34(1):71–7.CrossRef
29.
go back to reference Kucuk U, Pala EE, Sezer O, Cakir E, Bayol U, Divrik RT. Significance of TNM staging, demographic and histologic features in predicting the prognosis of renal cell carcinoma. Acta Chir Belg. 2015;115(3):202–7.CrossRef Kucuk U, Pala EE, Sezer O, Cakir E, Bayol U, Divrik RT. Significance of TNM staging, demographic and histologic features in predicting the prognosis of renal cell carcinoma. Acta Chir Belg. 2015;115(3):202–7.CrossRef
30.
go back to reference Lee C, You D, Yoo S, Song C, Hong B, Hong JH, Ahn H, Kim CS. Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy. J Cancer Res Clin Oncol. 2016;142(7):1651–7.CrossRef Lee C, You D, Yoo S, Song C, Hong B, Hong JH, Ahn H, Kim CS. Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy. J Cancer Res Clin Oncol. 2016;142(7):1651–7.CrossRef
31.
go back to reference van Oostenbrugge TJ, Kroeze SG, Bosch JL, van Melick HH. The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma. World J Urol. 2015;33(6):881–7.CrossRef van Oostenbrugge TJ, Kroeze SG, Bosch JL, van Melick HH. The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma. World J Urol. 2015;33(6):881–7.CrossRef
32.
go back to reference Tsui KH, Shvarts O, Smith RB, Figlin RA, de Kernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090–5 quiz 1295.CrossRef Tsui KH, Shvarts O, Smith RB, Figlin RA, de Kernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090–5 quiz 1295.CrossRef
33.
go back to reference Thiel DD, Jorns J, Lohse CM, Cheville JC, Thompson RH, Parker AS. Maximum tumor diameter is not an accurate predictor of renal cell carcinoma tumor volume. Scand J Urol. 2013;47(6):472–5.CrossRef Thiel DD, Jorns J, Lohse CM, Cheville JC, Thompson RH, Parker AS. Maximum tumor diameter is not an accurate predictor of renal cell carcinoma tumor volume. Scand J Urol. 2013;47(6):472–5.CrossRef
34.
go back to reference Wang S, Yang DM, Rong R, Zhan X, Fujimoto J, Liu H, Minna J, Wistuba II, Xie Y, Xiao G. Artificial Intelligence in Lung Cancer Pathology Image Analysis. Cancers. 2019;11(11):1673.CrossRef Wang S, Yang DM, Rong R, Zhan X, Fujimoto J, Liu H, Minna J, Wistuba II, Xie Y, Xiao G. Artificial Intelligence in Lung Cancer Pathology Image Analysis. Cancers. 2019;11(11):1673.CrossRef
35.
go back to reference Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol. 2019;16(7):391–403.CrossRef Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol. 2019;16(7):391–403.CrossRef
36.
go back to reference Nazari M, Shiri I, Hajianfar G, Oveisi N, Abdollahi H, Deevband MR, Oveisi M, Zaidi H. Noninvasive Fuhrman grading of clear cell renal cell carcinoma using computed tomography radiomic features and machine learning. Radiol Med. 2020;125(8):754–62.CrossRef Nazari M, Shiri I, Hajianfar G, Oveisi N, Abdollahi H, Deevband MR, Oveisi M, Zaidi H. Noninvasive Fuhrman grading of clear cell renal cell carcinoma using computed tomography radiomic features and machine learning. Radiol Med. 2020;125(8):754–62.CrossRef
Metadata
Title
Tumor volume: a new prognostic factor of oncological outcome of localized clear cell renal cell carcinoma
Authors
Shao-Hao Chen
Long-Yao Xu
Yu-Peng Wu
Zhi-Bin Ke
Peng Huang
Fei Lin
Xiao-Dong Li
Xue-Yi Xue
Yong Wei
Qing-Shui Zheng
Ning Xu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07795-8

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine